Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1970 1
1971 2
1972 1
1973 2
1974 2
1975 2
1976 5
1977 6
1978 18
1979 7
1980 5
1981 7
1982 12
1983 10
1984 11
1985 8
1986 11
1987 24
1988 33
1989 28
1990 40
1991 54
1992 84
1993 93
1994 111
1995 137
1996 122
1997 109
1998 121
1999 115
2000 110
2001 100
2002 121
2003 112
2004 149
2005 138
2006 136
2007 151
2008 121
2009 117
2010 119
2011 132
2012 137
2013 123
2014 121
2015 142
2016 109
2017 95
2018 122
2019 116
2020 138
2021 99
2022 82
2023 80
2024 91
2025 106
2026 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,931 results

Results by year

Filters applied: . Clear all
Page 1
Cerebral folate receptor autoantibodies in autism spectrum disorder.
Frye RE, Sequeira JM, Quadros EV, James SJ, Rossignol DA. Frye RE, et al. Mol Psychiatry. 2013 Mar;18(3):369-81. doi: 10.1038/mp.2011.175. Epub 2012 Jan 10. Mol Psychiatry. 2013. PMID: 22230883 Free PMC article. Clinical Trial.
Autism spectrum disorders (ASDs) and improvements in ASD symptoms with leucovorin (folinic acid) treatment have been reported in some children with CFD. In children with ASD, the prevalence of FRAs and the response to leucovorin in FRA-positive children has not been …
Autism spectrum disorders (ASDs) and improvements in ASD symptoms with leucovorin (folinic acid) treatment have been reported in some …
Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer.
Hartman AR, Grekowicz A, Lum BL, Carlson RW, Schurman C, Sikic BI, Shapiro R, Stockdale FE. Hartman AR, et al. Breast Cancer Res Treat. 2003 Nov;82(1):61-9. doi: 10.1023/B:BREA.0000003920.27391.ac. Breast Cancer Res Treat. 2003. PMID: 14672404 Clinical Trial.
PURPOSE: To determine the maximum tolerated doses, toxicities, and therapeutic effect of an oral chemotherapy regimen consisting of uracil-ftorafur, etoposide, and leucovorin for metastatic breast cancer. PATIENTS AND METHODS: The regimen consists of 28-day cycles of uraci …
PURPOSE: To determine the maximum tolerated doses, toxicities, and therapeutic effect of an oral chemotherapy regimen consisting of uracil-f …
[Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer].
Inoue K, Sugiura F, Kogita A, Yoshioka Y, Sukegawa Y, Hida J, Okuno K. Inoue K, et al. Gan To Kagaku Ryoho. 2014 Oct;41(10):1276-9. Gan To Kagaku Ryoho. 2014. PMID: 25335716 Clinical Trial. Japanese.
We conducted a clinical trial of a seven-peptide vaccine in combination with tegafur-uracil/Leucovorin for advanced colorectal cancer. These antigenic peptides were derived from 5 proteins identified as cancer-testis antigens(ring finger protein 43 [RNF43], translocase of …
We conducted a clinical trial of a seven-peptide vaccine in combination with tegafur-uracil/Leucovorin for advanced colorectal cancer …
Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.
Browman GP, Goodyear MD, Levine MN, Russell R, Archibald SD, Young JE. Browman GP, et al. J Clin Oncol. 1990 Feb;8(2):203-8. doi: 10.1200/JCO.1990.8.2.203. J Clin Oncol. 1990. PMID: 2405105 Review.
Randomized trials comparing high-dose methotrexate (HDMTX) plus leucovorin (LV) with standard-dose methotrexate (SDMTX) have not detected a therapeutic advantage for the HDMTX arm despite compelling evidence from experimental systems. ...
Randomized trials comparing high-dose methotrexate (HDMTX) plus leucovorin (LV) with standard-dose methotrexate (SDMTX) have not dete …
Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.
Garcia AA, Leichman L, Baranda J, Pandit L, Lenz HJ, Leichman CG. Garcia AA, et al. Int J Gastrointest Cancer. 2003;34(2-3):79-86. doi: 10.1385/IJGC:34:2-3:079. Int J Gastrointest Cancer. 2003. PMID: 15361639 Clinical Trial.
Preclinical studies suggest synergism between trimetrexate (TMTX),5-FU, and leucovorin (NFL). AIM: We conducted a phase II trial to evaluate the activity and safety of NFL in pancreatic cancer. METHOD: Eligible patients (n = 21) with untreated advanced pancreatic cancer we …
Preclinical studies suggest synergism between trimetrexate (TMTX),5-FU, and leucovorin (NFL). AIM: We conducted a phase II trial to e …
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
Saltz L, Badarinath S, Dakhil S, Bienvenu B, Harker WG, Birchfield G, Tokaz LK, Barrera D, Conkling PR, O'Rourke MA, Richards DA, Reidy D, Solit D, Vakiani E, Capanu M, Scales A, Zhan F, Boehm KA, Asmar L, Cohn A. Saltz L, et al. Clin Colorectal Cancer. 2012 Jun;11(2):101-11. doi: 10.1016/j.clcc.2011.05.006. Epub 2011 Nov 4. Clin Colorectal Cancer. 2012. PMID: 22055112 Clinical Trial.
BACKGROUND: Cetuximab (C), alone or with irinotecan, demonstrates activity in irinotecan-refractory colorectal cancer (CRC). Activity of 5-fluorouracil (5-FU), leucovorin (L), and bevacizumab (B), and preliminary data of cetuximab + bevacizumab, and toxicity profiles sugge …
BACKGROUND: Cetuximab (C), alone or with irinotecan, demonstrates activity in irinotecan-refractory colorectal cancer (CRC). Activity of 5-f …
Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer.
Huguier M, Barrier A, Valinas R, Flahault A, Adloff M, Pezet D, Jaeck D, Millat B; French University Association for Surgical Research. Huguier M, et al. Hepatogastroenterology. 2001 May-Jun;48(39):875-8. Hepatogastroenterology. 2001. PMID: 11462946 Clinical Trial.
BACKGROUND/AIMS: Phase II trials of combined 5 fluorouracil, leucovorin and cisplatin have demonstrated an 18-28% response rate in advanced pancreatic carcinomas. ...The trial was multicentric, prospective and randomized. It compared a 5-day course of leucovorin (20 …
BACKGROUND/AIMS: Phase II trials of combined 5 fluorouracil, leucovorin and cisplatin have demonstrated an 18-28% response rate in ad …
Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience.
Rustum YM. Rustum YM. J Chemother. 1990 Feb;2 Suppl 1:5-11. doi: 10.1080/1120009x.1990.11738998. J Chemother. 1990. PMID: 2195138 Review.
Recent laboratory preclinical results suggest that the major site of action of 5-fluorouracil when combined with 5-formyltetrahydrofolate (folinic acid, leucovorin) is thymidylate synthase resulting in pronounced and prolonged inhibition of DNA synthesis. ...In this paper, …
Recent laboratory preclinical results suggest that the major site of action of 5-fluorouracil when combined with 5-formyltetrahydrofolate (f …
Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer.
Yoshino T, Hyodo I, Nishina T, Narahara H, Sugimoto N, Yoshisue K, Boku N. Yoshino T, et al. Cancer Chemother Pharmacol. 2017 Jan;79(1):107-116. doi: 10.1007/s00280-016-3212-6. Epub 2016 Dec 8. Cancer Chemother Pharmacol. 2017. PMID: 27933371 Clinical Trial.
PURPOSE: S-1 has shown a response rate of 35% in chemonaive patients with metastatic colorectal cancer (mCRC). Leucovorin enhances the antitumor activity of 5-fluorouracil, and concurrent oral administration of S-1 and leucovorin may represent a more active treatmen …
PURPOSE: S-1 has shown a response rate of 35% in chemonaive patients with metastatic colorectal cancer (mCRC). Leucovorin enhances th …
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP. Saltz LB, et al. J Clin Oncol. 1996 Nov;14(11):2959-67. doi: 10.1200/JCO.1996.14.11.2959. J Clin Oncol. 1996. PMID: 8918493 Clinical Trial.
On day 1 of treatment, CPT-11 alone was given by 90-minute infusion, and pharmacokinetic sampling was performed over 24 hours. Leucovorin and 5FU were administered by brief intravenous injection on day 2. On days 8, 15, and 22, CPT-11 infusion was immediately followed by …
On day 1 of treatment, CPT-11 alone was given by 90-minute infusion, and pharmacokinetic sampling was performed over 24 hours. Leucovorin …
3,931 results